Measurement of anti-Aβ1-42 antibodies in intravenous immunoglobulin with indirect ELISA: The problem of nonspecific binding

Journal of Neuroscience Methods

Volumn 187, Issue 2, 2010, Pages 263-269

  Klaver, Andrea C ^a   Patrias, Lynnae M ^a   Coffey, Mary P ^a   Finke, John M ^b   Loeffler, David A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b OAKLAND UNIVERSITY   (United States)

Author keywords

: Alzheimer's disease; Amyloid beta; Anti amyloid beta antibodies; ELISA; Intravenous immunoglobulin; IvIg; Oligomers

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[1-42] ANTIBODY; HUMAN IMMUNOGLOBULIN; OLIGOMER; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); ANTIBODY; IMMUNOGLOBULIN; PEPTIDE FRAGMENT;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DILUTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; PRIORITY JOURNAL; PROTEIN BINDING; ANTIGEN ANTIBODY REACTION; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; WESTERN BLOTTING;

AMYLOID BETA-PROTEIN; ANTIBODIES; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY REACTIONS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PEPTIDE FRAGMENTS;

EID: 77249139928     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2010.01.018     Document Type: Article

References (45)

1. Arumugam T.V., Tang S.C., Lathia J.D., Cheng A., Mughal M.R., Chigurupati S., et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci USA 104 (2007) 14104-14109
2. Baril L., Nicolas L., Croisile B., Crozier P., Hessler C., Sassolas A., et al. Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer's disease and control subjects. Neurosci Lett 355 (2004) 226-230
3. Barten D.M., and Albright C.F. Therapeutic strategies for Alzheimer's disease. Mol Neurobiol 37 (2008) 171-186
4. Bobrovnik S.A. Specific and nonspecific interactions of antibodies and immunoglobulins with antigens and the methods of analysis of these interactions. Ukr Biokhim Zh 76 (2004) 132-139
5. Butler J.E., Peterman J.H., Suter M., and Dierks S.E. The immunochemistry of solid-phase sandwich enzyme-linked immunosorbent assays. Fed Proc 46 (1987) 2548-2556
6. Damianovich M., Blank M., Raiter A., Hardy B., and Shoenfeld Y. Anti-vascular endothelial growth factor (VEGF) specific activity of intravenous immunoglobulin (IVIg). Int Immunol 21 (2009) 1057-1063
7. Dodel R.C., Du Y., Depboylu C., Hampel H., Frölich L., Haag A., et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 75 (2004) 1472-1474
8. Dodel R., Hampel H., Depboylu C., Lin S., Gao F., Schock S., et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 52 (2002) 253-256
9. Fillit H., Hess G., Hill J., Bonnet P., and Toso C. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 73 (2009) 180-185
10. Frederix F., Bonroy K., Reekmans G., Laureyn W., Campitelli A., Abramov M.A., et al. Reduced nonspecific adsorption on covalently immobilized protein surfaces using poly(ethylene oxide) containing blocking agents. J Biochem Biophys Methods 58 (2004) 67-74
11. Gravina S.A., Ho L., Eckman C.B., Long K.E., Otvos Jr. L., Younkin L.H., et al. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem 270 (1995) 7013-7016
12. Gruden M.A., Davudova T.B., Malisauskas M., Zamotin V.V., Sewell R.D., Voskresenskaya N.I., et al. Autoimmune responses to amyloid structures of Abeta(25-35) peptide and human lysozyme in the serum of patients with progressive Alzheimer's disease. Dement Geriatr Cogn Disord 18 (2004) 165-171
13. Gustaw K.A., Garrett M.R., Lee H.G., Castellani R.J., Zagorski M.G., Prakasam A., et al. Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis. J Neurochem 106 (2008) 1350-1356
14. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 6 (1979) 65-70
15. Hyman B.T., Smith C., Buldyrev I., Whelan C., Brown H., Tang M.X., et al. Autoantibodies to amyloid-beta and Alzheimer's disease. Ann Neurol 49 (2001) 808-810
16. Istrin G., Bosis E., and Solomon B. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J Neurosci Res 84 (2006) 434-443
17. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., and Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13 (1994) 45-53
18. Jianping L., Zhibing Y., Wei Q., Zhikai C., Jie X., and Jinbiao L. Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease. Alzheimer Dis Assoc Disord 20 (2006) 127-132
19. Katz U., Achiron A., Sherer Y., and Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 6 (2007) 257-259
20. Kazatchkine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345 (2001) 747-755
21. Kenny G.E., and Dunsmoor C.L. Effectiveness of detergents in blocking nonspecific binding of IgG in the enzyme-linked immunosorbent assay (ELISA) depends upon the type of polystyrene used. Isr J Med Sci 23 (1987) 732-734
22. Kirkitadze M.D., Bitan G., and Teplow D.B. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J Neurosci Res 69 (2002) 567-577
23. Klaver A.C., Finke J.M., Digambaranath J., Balasubramaniam M., and Loeffler D.A. Antibody concentrations to Aβ1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations. Int Immunopharm 10 (2010) 115-119
24. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95 (1998) 6448-6453
25. Lee H.J., Namkoong K., Cho E.C., Ko C., Park J.C., and Lee S.S. Surface acoustic wave immunosensor for real-time detection of hepatitis B surface antibodies in whole blood samples. Biosens Bioelectron 24 (2009) 3120-3125
26. Li Q., Gordon M., Cao C., Ugen K.E., and Morgan D. Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC Neurosci 8 (2007) 22
27. Mann D.M., Iwatsubo T., Ihara Y., Cairns N.J., Lantos P.L., Bogdanovic N., et al. Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Am J Pathol 148 (1996) 1257-1266
28. Moir R.D., Tseitlin K.A., Soscia S., Hyman B.T., Irizarry M.C., and Tanzi R.E. Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem 280 (2005) 17458-17463
29. Nath A., Hall E., Tuzova M., Dobbs M., Jons M., Anderson C., et al. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromol Med 3 (2003) 29-39
30. Nerelius C., Johansson J., and Sandegren A. Amyloid beta-peptide aggregation. What does it result in and how can it be prevented?. Front Biosci 14 (2009) 1716-1729
31. Nimmerjahn F., and Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 26 (2008) 513-533
32. O'Nuallain B., Hrncic R., Wall J.S., Weiss D.T., and Solomon A. Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J Immunol 176 (2006) 7071-7078
33. Pellegrino N.M., and Caccavo D. Variability in anticardiolipin antibody detection: role of nonspecific IgG binding and different microtiter plates. Clin Appl Thromb Hemost 13 (2007) 404-409
34. Porat Y.B., Zan-Bar I., and Ravid A. Quantitative dot-blot assay for low titer anti-lipopolysaccharide antibodies in human plasma. J Immunol Methods 180 (1995) 213-218
35. Relkin N.R., Mujalli D.M., Shennoy S.A., Adamiak B., Weksler M.E., Kayed R., et al. IvIg contains antibodies against oligomers and fibrils of beta amyloid. Alzheimer Dement 3 (2007) S196
36. Relkin N.R., Szabo P., Adamiak B., Burgut T., Monthe C., Lent R.W., et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 30 (2009) 1728-1736
37. Scheinfeld N.S., and Godwin J.E. Intravenous immunoglobulin (2008), Emedicine. http://www.emedicine.com/med/topic3546.htm Mar 25, 2008 [http://www.emedicine.com/med/topic3546.htm]
38. Schreiner C., Musmanno L., Kuenzi M., and Torres J. Solid-phase immunoassays for HCV antibodies in Gamimune N. Vox Sang 74 (1998) 156-160
39. Seite J.F., Shoenfeld Y., Youinou P., and Hillion S. What is the contents of the magic draft IVIg?. Autoimmun Rev 7 (2008) 435-439
40. Shiwany N.A., Xie J., and Guo Q. Cortical neurons transgenic for human Abeta40 or Abeta42 have similar vulnerability to apoptosis despite their different amyloidogenic properties. Int J Clin Exp Pathol 2 (2009) 339-352
41. Shoenfeld Y., Rauova L., Gilburd B., Kvapil F., Goldberg I., Kopolovic J., et al. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 14 (2002) 1303-1311
42. Siegel J. The product: all intravenous immunoglobulins are not equivalent. Pharmacotherapy 25 (2005) 78S-84S
43. Song M.S., Mook-Jung I., Lee H.J., Min J.Y., and Park M.H. Serum anti-amyloid-beta antibodies and Alzheimer's disease in elderly Korean patients. J Int Med Res 35 (2007) 301-306
44. Szabo P., Relkin N., and Weksler M.E. Natural human antibodies to amyloid beta peptide. Autoimmun Rev 7 (2008) 415-420
45. Vani J., Elluru S., Negi V.S., Lacroix-Desmazes S., Kazatchkine M.D., Bayary J., et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev 7 (2008) 440-444